Moneycontrol PRO
Upcoming Webinar:Prashant Shah explains ‘Irrelevance of Bull & Bear Markets for Success in Technical Analysis’. Register For Free!
you are here: HomeNewsTrendsHealth

Will be able to manufacture, supply 10 crore Covishield doses in June: Serum Institute to Centre

In a recent letter to Union Home Minister Amit Shah, SII said its employees have been working round the clock in spite of various challenges because of the pandemic.

May 30, 2021 / 05:50 PM IST
Image: AP

Image: AP

Serum Institute of India (SII) has informed the government that it will be able to manufacture and supply nine to 10 crore doses of Covishield in June, official sources said on Sunday amid complaint by states about the shortage of anti-coronavirus vaccine jabs.

In a recent letter to Union Home Minister Amit Shah, SII said its employees have been working round the clock in spite of various challenges because of the pandemic.

Also Read: COVID-19 Vaccine Update: Nearly 12 crore jabs to be available for vaccination in June, says health ministry

"We are pleased to inform that in the month of June we will be able to manufacture and supply nine to 10 crore doses of our Covishield vaccine to the country as compared to our production capacity of 6.5 crore doses in May," Prakash Kumar Singh, the Director of Government and Regulatory Affairs at SII, said in the letter.

Follow our LIVE blog for latest updates of the novel coronavirus pandemic

Close

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

Singh also thanked Shah for his "valuable guidance and continuous support" at various stages of their endeavour to make India 'aatmanirbhar' (self-sufficient) in COVID-19 vaccines and making it available for the people of the country.

"Serum Institute of India has always been sincerely concerned about the protection of the citizens of our country and world at large from COVID-19. Under the leadership of our CEO, Adar C Poonawalla, our team have been working relentlessly shoulder to shoulder with our government to fight the COVID-19 pandemic," he said in the letter.

"We assure you that with the support of the Government of India and under your kind guidance, we are trying our best by utilizing all of our resources to increase our production capacity of Covishield in the coming month also."

In early May, SII had communicated to the Centre that production of Covishield would be ramped up to 6.5 crore in June, seven crore in July and 10 crore each in August and September.

India is currently using made-in-India vaccines -- Covishield manufactured by SII and Covaxin of Bharat Biotech -- in its COVID-19 immunisation programme.

The Russian Sputnik V is the third vaccine to get approval from the Drug Controller General of India (DCGI) for emergency use and is being used in a few private hospitals.

Follow our full coverage of the coronavirus pandemic here.
PTI

stay updated

Get Daily News on your Browser
Sections
ISO 27001 - BSI Assurance Mark